Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVIR NASDAQ:CABA NASDAQ:CRBU NASDAQ:OTLK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVIRAtea Pharmaceuticals$3.26+1.2%$3.20$2.45▼$4.02$258.71M0.22375,264 shs45,846 shsCABACabaletta Bio$2.68-5.1%$2.04$0.99▼$5.46$241.00M3.011.93 million shs1.06 million shsCRBUCaribou Biosciences$2.90+2.7%$2.07$0.66▼$3.00$269.59M2.591.28 million shs330,775 shsOTLKOncobiologics$1.43-3.7%$1.42$0.79▼$6.98$63.30M0.561.67 million shs248,305 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVIRAtea Pharmaceuticals+5.23%+3.54%+11.81%-6.12%-15.71%CABACabaletta Bio-1.05%+13.25%+28.77%+78.48%-42.51%CRBUCaribou Biosciences+7.22%+18.49%+66.86%+18.99%+41.00%OTLKOncobiologics+12.98%+12.98%+53.69%-28.85%-72.13%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVIRAtea Pharmaceuticals$3.26+1.2%$3.20$2.45▼$4.02$258.71M0.22375,264 shs45,846 shsCABACabaletta Bio$2.68-5.1%$2.04$0.99▼$5.46$241.00M3.011.93 million shs1.06 million shsCRBUCaribou Biosciences$2.90+2.7%$2.07$0.66▼$3.00$269.59M2.591.28 million shs330,775 shsOTLKOncobiologics$1.43-3.7%$1.42$0.79▼$6.98$63.30M0.561.67 million shs248,305 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVIRAtea Pharmaceuticals+5.23%+3.54%+11.81%-6.12%-15.71%CABACabaletta Bio-1.05%+13.25%+28.77%+78.48%-42.51%CRBUCaribou Biosciences+7.22%+18.49%+66.86%+18.99%+41.00%OTLKOncobiologics+12.98%+12.98%+53.69%-28.85%-72.13%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVIRAtea Pharmaceuticals 2.00Hold$6.0084.05% UpsideCABACabaletta Bio 2.82Moderate Buy$13.44402.60% UpsideCRBUCaribou Biosciences 2.50Moderate Buy$6.67130.28% UpsideOTLKOncobiologics 2.14Hold$7.00391.23% UpsideCurrent Analyst Ratings BreakdownLatest OTLK, CRBU, CABA, and AVIR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/10/2025CABACabaletta BioJefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$14.0010/10/2025CABACabaletta BioHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$16.0010/8/2025AVIRAtea PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025CABACabaletta BioWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025CRBUCaribou BiosciencesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025OTLKOncobiologicsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/30/2025OTLKOncobiologicsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral9/27/2025AVIRAtea PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025CABACabaletta BioWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025CRBUCaribou BiosciencesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025OTLKOncobiologicsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 10/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVIRAtea PharmaceuticalsN/AN/AN/AN/A$5.20 per shareN/ACABACabaletta BioN/AN/AN/AN/A$3.12 per shareN/ACRBUCaribou Biosciences$9.12M29.56N/AN/A$2.79 per share1.04OTLKOncobiologicsN/AN/AN/AN/A($3.09) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVIRAtea Pharmaceuticals-$168.38M-$1.61N/AN/AN/AN/A-32.55%-30.47%11/6/2025 (Estimated)CABACabaletta Bio-$115.86M-$2.71N/AN/AN/AN/A-92.11%-74.08%11/13/2025 (Estimated)CRBUCaribou Biosciences-$149.10M-$1.78N/AN/AN/A-1,800.93%-62.35%-49.65%11/5/2025 (Estimated)OTLKOncobiologics-$75.37M-$0.57N/AN/AN/AN/AN/A-332.30%12/26/2025 (Estimated)Latest OTLK, CRBU, CABA, and AVIR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/13/2025Q3 2025CABACabaletta Bio-$0.52N/AN/AN/AN/AN/A11/6/2025Q3 2025AVIRAtea Pharmaceuticals-$0.46N/AN/AN/AN/AN/A11/5/2025Q3 2025CRBUCaribou Biosciences-$0.36N/AN/AN/AN/AN/A8/14/2025Q3 2025OTLKOncobiologics-$0.42-$0.44-$0.02-$0.55$1.66 million$1.51 million8/12/2025Q2 2025CRBUCaribou Biosciences-$0.40-$0.35+$0.05-$0.58$1.64 million$2.67 million8/7/2025Q2 2025AVIRAtea Pharmaceuticals-$0.46-$0.44+$0.02-$0.44N/AN/A8/7/2025Q2 2025CABACabaletta Bio-$0.71-$0.73-$0.02-$0.73$4.17 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVIRAtea PharmaceuticalsN/AN/AN/AN/AN/ACABACabaletta BioN/AN/AN/AN/AN/ACRBUCaribou BiosciencesN/AN/AN/AN/AN/AOTLKOncobiologicsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVIRAtea PharmaceuticalsN/A19.1719.17CABACabaletta BioN/A4.784.78CRBUCaribou BiosciencesN/A6.666.66OTLKOncobiologicsN/A0.670.54Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVIRAtea Pharmaceuticals86.67%CABACabaletta BioN/ACRBUCaribou Biosciences77.51%OTLKOncobiologics11.20%Insider OwnershipCompanyInsider OwnershipAVIRAtea Pharmaceuticals18.10%CABACabaletta Bio11.25%CRBUCaribou Biosciences8.28%OTLKOncobiologics4.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVIRAtea Pharmaceuticals7079.36 million64.99 millionOptionableCABACabaletta Bio5091.46 million81.18 millionOptionableCRBUCaribou Biosciences10093.12 million84.28 millionOptionableOTLKOncobiologics2044.42 million42.29 millionOptionableOTLK, CRBU, CABA, and AVIR HeadlinesRecent News About These CompaniesOncobiologics, Inc. (NASDAQ:OTLK) Given Consensus Rating of "Hold" by BrokeragesOctober 19 at 2:05 AM | marketbeat.comWeiss Ratings Reaffirms "Sell (E+)" Rating for Oncobiologics (NASDAQ:OTLK)October 10, 2025 | marketbeat.comOutlook Therapeutics Provides Update on Type A Meeting with FDASeptember 29, 2025 | globenewswire.comOutlook Therapeutics to Present at the 2025 EURETINA Innovation Spotlight (EIS)September 3, 2025 | globenewswire.comOutlook Therapeutics Requests Type A Meeting with FDASeptember 2, 2025 | globenewswire.comOTLK Stock Crashes 54% as FDA Issues Second CRL for Eye Disease DrugAugust 29, 2025 | zacks.comUS FDA declines to approve Outlook Therapeutics' drug for eye conditionAugust 28, 2025 | reuters.comOutlook Therapeutics Provides Regulatory Update on U.S. Food and Drug Administration Review of ONS-5010/LYTENAVA™ (bevacizumab-vikg) for the Treatment of Wet AMDAugust 28, 2025 | globenewswire.comOutlook Therapeutics: Why The Odds Point To A Favorable FDA DecisionAugust 24, 2025 | seekingalpha.comOncobiologics, Inc. (OTLK) Reports Q3 Loss, Lags Revenue EstimatesAugust 14, 2025 | zacks.comOutlook Therapeutics Reports Financial Results for Third Quarter Fiscal Year 2025 and Provides Corporate UpdateAugust 14, 2025 | globenewswire.comNew Strong Buy Stocks for July 30thJuly 30, 2025 | zacks.comOutlook Therapeutics to Present at the 8th Annual Ophthalmology Innovation Summit (OIS) Retina Innovation ShowcaseJuly 24, 2025 | globenewswire.comOutlook Therapeutics Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand ConferenceJuly 22, 2025 | globenewswire.comOTLK Outlook Therapeutics, Inc. - Seeking AlphaJuly 2, 2025 | seekingalpha.comOutlook Therapeutics Appoints Biopharmaceutical Industry and Commercial Leader Bob Jahr as Chief Executive OfficerJuly 1, 2025 | globenewswire.comOutlook Therapeutics to Participate in a Virtual Investor Lunch Break EventJune 18, 2025 | globenewswire.comMicrosoft shares temp fix for Outlook crashes when opening emailsJune 17, 2025 | bleepingcomputer.comBCFA Institute 2025 Graduate Outlook Survey: Finance Top Career ChoiceJune 12, 2025 | tmcnet.comSteve Wilks Pleased With Jets Defensive OutlookJune 12, 2025 | msn.comMicrosoft Outlook to block more risky attachments used in attacksJune 12, 2025 | bleepingcomputer.comBNew MarketBeat Followers Over TimeMedia Sentiment Over TimeOTLK, CRBU, CABA, and AVIR Company DescriptionsAtea Pharmaceuticals NASDAQ:AVIR$3.26 +0.04 (+1.24%) As of 11:00 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19. It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of Ruzasvir, an NS5A inhibitor, for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.Cabaletta Bio NASDAQ:CABA$2.68 -0.15 (-5.14%) As of 11:00 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, which is in Phase I/II clinical trial for the treatment of mucosal pemphigus vulgaris; and MuSK-CAART, an investigational cell therapy that is in Phase I/II clinical trial for treating patients with anti- muscle-specific kinase antibody positive myasthenia gravis. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.Caribou Biosciences NASDAQ:CRBU$2.90 +0.08 (+2.66%) As of 11:00 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.Oncobiologics NASDAQ:OTLK$1.42 -0.06 (-3.72%) As of 11:00 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Will D-Wave's European Expansion Keep Fueling the Rally? Navitas Soars 78% on NVIDIA Update: Is This Rally Sustainable? Louis Vuitton Earnings Show Luxury Bull Market Isn’t Done Yet Waymo’s Global Expansion Strengthens the Case for GOOGL Stock Broadcom Inks OpenAI Deal: Why It's A Huge Win for AVGO Stock Meta vs OpenAI: Is Sora a True Threat to Meta's Dominance? Institutions Are Fueling CrowdStrike’s Next Leg Higher This AI Chip Giant Could Be the Market’s Next Big Winner Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
